Inhibition of lipoprotein lipase induced cholesterol ester accumulation in human hepatoma HepG2 cells

Atherosclerosis

Volumn 120, Issue 1-2, 1996, Pages 101-114

  Cianflone, Katherine ^a   Avramoglu, Rita Kohen ^b   Sawyez, Cynthia ^a   Huff, Murray W ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Hepatocyte; Lipoproteins; Proteoglycan; VLDL

Indexed keywords

CHOLESTEROL ESTER; LIPOPROTEIN LIPASE; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; HEPATOMA CELL; HUMAN; HUMAN CELL; HYPERTRIGLYCERIDEMIA; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0342538910     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(95)05690-4     Document Type: Article

References (69)

1. Packard CJ, Munro A, Lorimer AR, Gotto AM, Shepherd J. Metabolism of apolipoprotein B in large triglyce-ride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects. J Clin Invest 1984;74:2178.
2. Barbir M, Wile D, Trayner I, Aber VR, Thompson GR. High prevalence of hypertrigliceridaemia and apolipoprotein abnormalities in coronary artery disease. Br Heart J 1988;60:397.
3. Huff MW, Breckenridge WC, Strong WLP, Wolfe BM. Metabolism of apolipoproteins C-II, C-III, and B in hypertrigliceridemic men. Changes after heparin induced lipolysis. Arteriosclerosis 1988;8:471.
4. Shepherd J, Packard CJ. Metabolic heterogeneity in very low-density lipoproteins. Am Heart J 1987;113:503.
5. Dashti N, Wolfbauer G. Studies on the binding and degradation of human very-low-density lipoproteins by human hepatoma cell line HepG2. Biochim Biophys Acta 1986;875:473.
6. Krempler F, Kostner GM, Friedl W, Paulweber B, Bauer J, Sandhofer F. Lipoprotein binding to cultured human hepatoma cells. J Clin Invest 1987;80:401.
7. Huff MW, Evans AJ, Sawyez CG, Wolfe BM, Nestel PJ. Cholesterol accumulation in J774 macrophages induced by triglyceride-rich lipoproteins: comparison of very low density lipoprotein from subjects with type III, IV, and V hyperlipoproteinemias. Arteriosclerosis Thromb 1991;11: 221.
8. Evans AJ, Sawyez CG, Wolfe BM, Huff MW. Lipolysis is a prerequisite for lipid accumulation in HepG2 cells induced by large hypertriglyceridemic very low density lipoproteins. J Biol Chem 1992;267:10 743.
9. Evans AJ, Sawyez CG, Wolfe BM, Connelly PW, Maguire GF, Huff MW, Evidence that cholesteryl ester and triglyceride accumulation in J774 macrophages induced by very low density lipoprotein subfractions occurs by different mechanisms. J Lipid Res 1993;34:703.
10. Beisiegel U, Weber W, Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc Natl Acad Sci USA 1991;88:8342.
11. 2-macroglobulin receptor in vitro. J Biol Chem 1993;68:14 168.
12. Mulder M, Lombardi P, Jansen H, van Berkel T, Frants FR, Havekes LM. Heparan sulphate proteoglycans are involved in the lipoprotein lipase-mediated enhancement of the cellular binding of very low density and low density lipoproteins. Biochem Biophys Res Commun 1992; 185:582.
13. Mulder M, Lombardi P, Jansen H, van Berkel T, Frants RH, Havekes LM. Low density lipoprotein receptor internalizes low density and very low density lipoproteins that are bound to heparan sulfate proteoglycans via lipoprotein lipase. J Biol Chem 1993;268:9369.
14. Eisenberg S, Sehayek E, Olivecrona T, Vlodavsky I. Lipoprotein lipase enhances binding of lipoproteins to heparan sulfate on cell surfaces and extracellular matrix. J Clin Invest 1992;90:2013.
15. Saxena U, Klein MG, Vanni TM, Goldberg IJ. Lipoprotein lipase increases low density lipoprotein retention by subendothelial cell matrix. J Clin Invest 89:373.
16. Rumsey SC, Obunike JC, Arad Y, Deckelbaum RJ, Goldberg IJ. Lipoprotein lipase-mediated uptake and degradation of low density lipoproteins by fibroblasts and macrophages. J Clin Invest 1992;90:1504.
17. Williams KJ, Fless GM, Petrie KA, Snyder ML, Brocia RW, Swenson TL. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins. J Biol Chem 1992;267:13 284.
18. Schaefer EJ, Levy RI. Pathogenesis and management of lipoprotein disorders. N Engl J Med 1985;312:1300.
19. Bouthillier D, Sing CF, Davignon J. Apolipoprotein E phenotyping with a single gel method: application to the study of informative matings. J Lipid Res 1983;24:1060.
20. Havel R, Eder H, Bragson. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345.
21. Goldberg IJ, Le NA, Ginsberg HN, Krauss RM, Lindgren FT. Lipoprotein metabolism during acute inhibition of lipoprotein lipase in the cynomologus monkey. J Clin Invest 1988;81:561.
22. Markwell MK, Haas SM, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 1978;87:206.
23. Neri BP, Frings CS. Improved method for determination of triglycerides in serum. Clin Chem 1973;19:1201.
24. Rudel LL, Morris MD. Determination of cholesterol using θ-pthalaldehyde. J Lipid Res 1973;14:364.
25. Socorro L, Jackson RL. Monoclonal antibodies to milk lipoprotein lipase. Evidence for proteolytic degradation of the native enzyme. J Biol Chem 1985;260:6324.
26. Huff MW, Evans AJ, Wolfe BM, Connelly PW, Maguire GF, Strong WLP. Identification and metabolic characteristics of an apolipoprotein C-II variant isolated from a hypertriglyceridemic subject. J Lipid Res 1990;31:385.
27. Peterson J, Bihain BE, Bengtsson-Olivecrona G, Deckelbaum RJ, Carpentier YA, Olivecrona T. Fatty acid control of lipoprotein lipase: a link between energy metabolism and lipid transport. Proc Natl Acad Sci USA 1990;87:909.
28. Milne RW, Marcel YL. Monoclonal antibodies against human low density lipoprotein. Stoichiometric binding studies using Fab fragments. FEBS Lett 1983;146:97.
29. Weisgraber KH, Innerarity TL, Harder KJ, Mahley RW, Milne RW, Marcel YL, Sparrow JT. The receptor-binding domain of human apolipoprotein E. J Biol Chem 1983;258:12 348.
30. Krul ES, Tikkanen MJ, Cole TG, Davie JM, Schonfeld G. Roles of apolipoproteins B and E in the cellular binding of very low density lipoprotein. J Clin Invest 1985;75:361.
31. Marcel YL, Hogue M, Weech PK, Davignon J, Milne RW. Expression of apolipoprotein B epitopes in lipoproteins. Relationship to conformation and function. Arteriosclerosis 1988;8:832.
32. Milne RW, Theolis R Jr, Marcel YL. Characterization of monoclonal antibodies against human low density lipoproteins. Arteriosclerosis 1983;3:23.
33. Benzonana G. Some properties of an exocellular lipase from Rhizopus arrhizus. Lipids 1974;9:166.
34. Antonian E. Recent advances in the purification, characterization and structure determination of lpases. Lipids 1988;23:1101.
35. Windler E, Greeve G, Levkau B, Kolb-Bachofen V, Daerr W, Greten H. The human asialoglycoprotein receptor is a possible binding site for low-density lipoproteins and chylomicron remnants. Biochem J 1991;276:79.
36. Willnow TE, Goldstein JL, Orth K, Brown MS, Herz J. Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. J Biol Chem 1992;267: 26 172.
37. Ziere GJ, van Dijk MC, Bijsterbosch MK, van Berkel TJ. Lactoferrin uptake by the rat liver. J Biol Chem 1992;267:11 229.
38. Geuze HJ, vas der Donk HA, Simmons CF, Slot JW, Strous GJ, Schwartz HL. Receptor-mediated endocytosis in liver parenchymal cells. Int Rev Exp Pathol 1986;29: 113.
39. Persson E. Lipoprotein lipase, hepatic lipase, and plasma lipolytic activity: effects of heparin and a low molecular weight heparin fragment (Fragmin). Acta Med Scand 1988(Suppl);724:1.
40. Peterson J, Fujimoto W, Brunzell J. Human lipoprotein lipase: relationship of activity, and conformation as studies with monoclonal antibodies. J Lipid Res 1992;33:1165.
41. 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds lipoprotein lipase and β-migrating very low density lipoprotein associated with the lipase. J Biol Chem 1993;268:15 048.
42. Hamilton RL, Wong JS, Guo LSS, Krisans S, Havel RJ. Apolipoprotein E localization in rat hepatocytes by immunogold labeling of cryothin sections. J Lipid Res 1990;31:1589.
43. Fazio S, Yao Z, McCarthy BJ, Rail SC Jr. Synthesis and secretion of apolipoprotein E occur independently of synthesis and secretion of apolipoprotein B-containing lipoproteins in HepG2 cells. J Biol Chem 1992;267:6941.
44. Mahley RW, Hussain MM. Chylomicron and chylomicron remnant catabolism. Curr Opin Lipidol 1991;2:170.
45. Mokuno H, Yamada N, Shimano H, Ishibashi S, Mori N, Takahashi K, Oka T, Yoon TH, Takaku F. The enhanced cellular uptake of very low-density lipoprotein enriched in apolipoprotein E. Biochim Biophys Acta 1991;1082:63.
46. Leblond L, Marcel YL. Uptake of high density lipoprotein cholesterol ester by HepG2 cells involves apolipoprotein E localized on the cell surface. J Biol Chem 1993;268:1670.
47. Lilly-Stauderman M, Brown TL, Balasubramaniam A, Harmony JAK. Heparin releases newly synthesized cell surface-associated apolipoprotein E from HepG2 cells. J Lipid Res 1993;34:190.
48. Shimano H, Namba Y, Ohsuga J, Kawamura M, Yamamoto K, Shimada M, Gotoda T, Harada K, Yazaki Y, Yamada, N. Secretion-recapture process of apolipoprotein E in hepatic uptake of chylomicron remnants in transgenic mice. J Clin Invest 1994;93:2215.
49. Ji SZ, Brecht WJ, Miranda RD, Hussain MM, Innerarity, TL, Mahley RW. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J Biol Chem 1993;268:10 160.
50. Hu WL, Regoec E, Chindemi PA, Bolyos M. Lactoferrin interferes with uptake of iron from transferrin and asialotransferrin by the rat liver. Am J Physiology 1993;264:G112.
51. Jackson RL, Busch SJ, Cardin AD. Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev 1991;71:481.
52. Camejo G, Hurt-Camejo E, Bondjers G. Effect of proteoglycans on lipoprotein-cell interactions: possible contribution to atherogenesis. Curr Opin Lipidol 1990;1:431.
53. Clowes AW, Karnovsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977;265:625.
54. Gitag-Goren H, Sokes S, Vlodavsky I, Neufiels G. The binding of vascular endothelial growth factor to its receptor is dependent on cell surface-associated heparin-like molecules. J Biol Chem 1992;267:6093.
55. Sakaguchi K, Yanagishita M, Yasuhiro T, Aurbach GD. Identification of heparan sulfate proteoglycan as a high affinity receptor for acidic fibroblast growth factor (aFGF) in a parathyroid cell line. J Biol Chem 1991; 266:7270.
56. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991;64:841.
57. Rapraeger AC, Krufka A, Olwin BB. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 1991;252:1705.
58. Reid LM, Abreu SL, Montgomery K. In: Arias IM, Jacoby WB, Popper H, Schachter D and Shafritz. (eds). The Liver: Biology and Pathobiology, 2nd Edn New York: Raven Press, 1988;717.
59. Spray DC, Fujita M, Saez JC, Choi H, Watanabe T, Hertzberg E, Rosenberg LC, Reid LM. Proteoglycans and glycosaminoglycans induce gap junction synthesis and function in primary liver cultures. J Cell Biol 1987; 105:541.
60. Fujita M, Spray DC, Choi H, Saez JC, Watanabe T, Rosinberg LC, Hertzberg EL, Reid LM. Glycosaminoglycans and proteoglycans induce gap junction expression and restore transcription of tissue-specific mRNAs in primary liver cultures. Hepatology 1987;7:1S.
61. Gressner AM, Vasel A. Developmental changes of proteoglycan synthesis in rat liver and isolated hepatocytes. Mech Aging Dev 1985;31:307.
62. Bradley WA, Hwang SC, Karlin JB, Lin AHY, Prasad SC, Gotto AM, Gianturco SH. Low-density lipoprotein receptor binding determinant switch from apolipoprotein E to apolipoprotein B during conversion of hypertriglyceridemic very-low-density lipoprotein to low-density lipoprotein. J Biol Chem 1984;259:14 728.
63. Goldstein JL, Basu SK, Brunschede GY, Brown MS. Release of low density lipoprotein from its cell surface receptor by sulfated glycosaminoglycans. Cell 1976;7: 85.
64. Oswald B, Shelbourne F, Landis B, Linker A, Quarfordt S. The relevance of glycosaminoglycan sulfates to apoE induced lipid uptake by hepatocyte monolayers. Biochem Biophys Res Commun 1986;141:158.
65. Ji SZ, Mahley TL. Lactoferrin binding to heparan sulfate proteoglycans and the LDL receptor-related protein: further evidence supporting the importance of direct binding of remnant lipoproteins to HSPG. Arteriosclerosis Thromb 1994;14:2025.
66. Ziere GJ, Kruijt JK, Bijsterbosch MK, van Berkel TJC. Recognition of lactoferrin and aminopeptidase M-modified lactoferrin by the liver: involvement of proteoglycans and the remnant receptor. Atherosclerosis 1994; 109:113.
67. Vilaro S, Llobera M, Bengtsson-Olivecrona G, Olivecrona T. Lipoprotein lipase uptake by the liver: localization, turnover, and metabolic role. Am J Physiol 1988; 254:G711.
68. Vilella E, Joven J, Fernandez M, Vilaro S, Brunzell JD, Olivecrona T, Bengtsson-Olivecrona G. Lipoprotein lipase in human plasma is mainly inactive and associated with cholesterol-rich lipoproteins. J Lipid Res 1993;34: 1555.
69. Goldberg IJ, Kandel JJ, Blum CB, Ginsberg HN. Association of plasma lipoprotein with postheparin lipase activities. J Clin Invest 1986;78:1523.